Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Accenture
Teva
Moodys
McKinsey

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 9,879,325

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,879,325
Title:Method for predicting the responsiveness a patient to a treatment with an anti-CD20 antibody
Abstract: The present invention relates to a method for predicting the responsiveness of a patient to a treatment with an anti-CD20 antibody, said method comprising measuring the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in B cells obtained from said patient.
Inventor(s): Chiche; Johanna (Nice, FR), Thieblemont; Catherine (Paris, FR), Ricci; Jean-Ehrland (Nice, FR)
Assignee: ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DIDEROT (PARIS VII) (Paris, FR) UNIVERSITE DE NICE--SOPHIA ANTIPOLIS (Nice, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (Paris, FR)
Application Number:15/121,864
Patent Claims:see list of patent claims

Details for Patent 9,879,325

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26 ➤ Sign Up ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DIDEROT (PARIS VII) (Paris, FR) UNIVERSITE DE NICE--SOPHIA ANTIPOLIS (Nice, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (Paris, FR) 2034-03-03 RX search
Glaxo Grp Ltd ARZERRA ofatumumab INJECTABLE; INJECTION 125326 001 2009-10-26 ➤ Sign Up ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DIDEROT (PARIS VII) (Paris, FR) UNIVERSITE DE NICE--SOPHIA ANTIPOLIS (Nice, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (Paris, FR) 2034-03-03 RX search
Genentech Inc OCREVUS ocrelizumab INJECTABLE;INJECTION 761053 001 2017-03-28 ➤ Sign Up ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DIDEROT (PARIS VII) (Paris, FR) UNIVERSITE DE NICE--SOPHIA ANTIPOLIS (Nice, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (Paris, FR) 2034-03-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Boehringer Ingelheim
Mallinckrodt
Healthtrust
Federal Trade Commission
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.